(NBIX) Neurocrine Biosciences - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 13.296m USD | Total Return: 42.1% in 12m

Neurological Drugs, Endocrine Drugs, Psychiatric Drugs
Total Rating 56
Safety 86
Buy Signal 0.23
Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.4
Market Cap: 13.3B
Avg Turnover: 117M USD
ATR: 3.03%
Peers RS (IBD): 22.3
Risk 5d forecast
Volatility34.2%
Rel. Tail Risk-15.7%
Reward TTM
Sharpe Ratio1.00
Alpha28.86
Character TTM
Beta0.413
Beta Downside-0.799
Drawdowns 3y
Max DD42.89%
CAGR/Max DD0.18
EPS (Earnings per Share) EPS (Earnings per Share) of NBIX over the last years for every Quarter: "2021-03": 0.33, "2021-06": 0.43, "2021-09": 0.64, "2021-12": -0.08, "2022-03": 0.14, "2022-06": -0.18, "2022-09": 0.69, "2022-12": 0.88, "2023-03": -0.79, "2023-06": 0.95, "2023-09": 0.82, "2023-12": 1.44, "2024-03": 0.42, "2024-06": 0.63, "2024-09": 1.81, "2024-12": 1.69, "2025-03": 0.7, "2025-06": 1.65, "2025-09": 2.17, "2025-12": 1.88, "2026-03": 0,
EPS CAGR: 6.33%
EPS Trend: 45.3%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of NBIX over the last years for every Quarter: 2021-03: 236.6, 2021-06: 288.9, 2021-09: 296, 2021-12: 312, 2022-03: 310.6, 2022-06: 378.2, 2022-09: 387.9, 2022-12: 412, 2023-03: 420.4, 2023-06: 452.7, 2023-09: 498.8, 2023-12: 515.2, 2024-03: 515.3, 2024-06: 590.2, 2024-09: 622.1, 2024-12: 627.7, 2025-03: 572.6, 2025-06: 687.5, 2025-09: 794.9, 2025-12: 805.5, 2026-03: null,
Rev. CAGR: 28.93%
Rev. Trend: 97.8%
Last SUE: 0.85
Qual. Beats: 3

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: NBIX Neurocrine Biosciences

Neurocrine Biosciences Inc. (NBIX) is a biotechnology company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders.

The companys product portfolio includes treatments for tardive dyskinesia, endometriosis, uterine fibroids, and congenital adrenal hyperplasia. NBIX also has a pipeline of drug candidates in clinical development for various conditions, including movement disorders, major depressive disorder, schizophrenia, epilepsy, and Alzheimers disease. The biotechnology sector is characterized by lengthy and expensive research and development processes, often spanning over a decade from discovery to market.

NBIX employs a business model that includes both proprietary drug development and strategic collaborations. They have licensing and collaboration agreements with several pharmaceutical companies, which can provide funding, shared development costs, and broader market access. For further details on NBIXs specific drug pipeline and market performance, ValueRay offers in-depth analysis.

Headlines to Watch Out For
  • INGREZZA sales growth drives revenue expansion
  • Pipeline development success impacts future revenue
  • Regulatory approvals for new drugs create market opportunities
  • Collaboration agreements influence R&D costs and revenue sharing
Piotroski VR‑10 (Strict) 6.0
Net Income: 478.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA 1.18 > 1.0
NWC/Revenue: 62.20% < 20% (prev 51.67%; Δ 10.53% < -1%)
CFO/TA 0.17 > 3% & CFO 782.7m > Net Income 478.6m
Net Debt (-1.07b) to EBITDA (719.1m): -1.48 < 3
Current Ratio: 3.39 > 1.5 & < 3
Outstanding Shares: last quarter (102.5m) vs 12m ago -0.39% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 68.51% > 50% (prev 63.34%; Δ 5.18% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 4.30
A: 0.38 (Total Current Assets 2.52b - Total Current Liabilities 743.4m) / Total Assets 4.63b
B: 0.10 (Retained Earnings 447.7m / Total Assets 4.63b)
C: 0.17 (EBIT TTM 689.0m / Avg Total Assets 4.18b)
D: 0.33 (Book Value of Equity 460.9m / Total Liabilities 1.38b)
Altman-Z'' Score: 4.30 = AA
Beneish M -2.85
DSRI: 1.18 (Receivables 686.8m/479.1m, Revenue 2.86b/2.36b)
GMI: 1.00 (GM 98.18% / 98.56%)
AQI: 0.90 (AQ_t 0.34 / AQ_t-1 0.38)
SGI: 1.21 (Revenue 2.86b / 2.36b)
TATA: -0.07 (NI 478.6m - CFO 782.7m) / TA 4.63b)
Beneish M-Score: -2.85 (Cap -4..+1) = A
What is the price of NBIX shares? As of April 12, 2026, the stock is trading at USD 128.89 with a total of 792,080 shares traded.
Over the past week, the price has changed by -2.71%, over one month by -0.75%, over three months by -2.84% and over the past year by +42.07%.
Is NBIX a buy, sell or hold? Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.
  • StrongBuy: 15
  • Buy: 7
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the NBIX price?
Analysts Target Price 178 38.1%
Neurocrine Biosciences (NBIX) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 28.3683
P/E Forward = 23.1481
P/S = 4.6482
P/B = 4.0598
P/EG = 0.3571
Revenue TTM = 2.86b USD
EBIT TTM = 689.0m USD
EBITDA TTM = 719.1m USD
Long Term Debt = 415.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.3m USD (from shortTermDebt, two quarters ago)
Debt = 415.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.07b USD (recalculated: Debt 415.3m - CCE 1.48b)
Enterprise Value = 12.23b USD (13.30b + Debt 415.3m - CCE 1.48b)
 Interest Coverage Ratio = unknown (Ebit TTM 689.0m / Interest Expense TTM 0.0)
 EV/FCF = 16.34x (Enterprise Value 12.23b / FCF TTM 748.7m)
FCF Yield = 6.12% (FCF TTM 748.7m / Enterprise Value 12.23b)
FCF Margin = 26.17% (FCF TTM 748.7m / Revenue TTM 2.86b)
Net Margin = 16.73% (Net Income TTM 478.6m / Revenue TTM 2.86b)
 Gross Margin = unknown ((Revenue TTM 2.86b - Cost of Revenue TTM 52.1m) / Revenue TTM)
 Tobins Q-Ratio = 2.64 (Enterprise Value 12.23b / Total Assets 4.63b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 415.3m)
Taxrate = 35.80% (85.7m / 239.4m)
NOPAT = 442.4m (EBIT 689.0m * (1 - 35.80%))
Current Ratio = 3.39 (Total Current Assets 2.52b / Total Current Liabilities 743.4m)
Debt / Equity = 0.13 (Debt 415.3m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -1.48 (Net Debt -1.07b / EBITDA 719.1m)
Debt / FCF = -1.42 (Net Debt -1.07b / FCF TTM 748.7m)
Total Stockholder Equity = 2.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.46% (Net Income 478.6m / Total Assets 4.63b)
RoE = 16.67% (Net Income TTM 478.6m / Total Stockholder Equity 2.87b)
RoCE = 20.96% (EBIT 689.0m / Capital Employed (Equity 2.87b + L.T.Debt 415.3m))
RoIC = 15.40% (NOPAT 442.4m / Invested Capital 2.87b)
WACC = 7.21% (E(13.30b)/V(13.71b) * Re(7.44%) + D(415.3m)/V(13.71b) * Rd(0.0%) * (1-Tc(0.36)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF] Terminal Value 84.20% ; FCFF base≈672.1m ; Y1≈829.1m ; Y5≈1.41b
[DCF] Fair Price = 299.4 (EV 28.98b - Net Debt -1.07b = Equity 30.05b / Shares 100.4m; r=7.21% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 45.28 | EPS CAGR: 6.33% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.77 | Revenue CAGR: 28.93% | SUE: 0.85 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.99 | Chg7d=+0.001 | Chg30d=-0.226 | Revisions Net=-4 | Analysts=14
EPS current Year (2026-12-31): EPS=7.96 | Chg7d=+0.006 | Chg30d=-1.175 | Revisions Net=-4 | Growth EPS=+24.5% | Growth Revenue=+20.4%
EPS next Year (2027-12-31): EPS=9.72 | Chg7d=+0.138 | Chg30d=-1.003 | Revisions Net=-3 | Growth EPS=+22.1% | Growth Revenue=+10.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +19.1% (Analyst 23.5% - Implied 4.4%)
External Resources
Dataroma Stockcircle